Abionic
@abionic.com
The winner of multiple industry awards, including "Swiss MedTech of the year" in 2023, Abionic is a Swiss MedTech company spun-out of EPFL in 2010 on a vision nanofluidics could transform diagnostics. Our flagship abioSCOPE®, a near-patient rapid diagnostic platform, delivers lab-quality results from a drop of blood within minutes, providing valuable clinical insights and actionable information at the point-of-care.
Abionic's Company Logos
Abionic's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#06AEB5
Pacific Blue
6, 174, 181
182, 94, 37
97, 4, 0, 29
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#147B86
Surfie Green
20, 123, 134
186, 74, 30
85, 8, 0, 47
About Abionic
Abionic_EN is a brand committed to revolutionizing healthcare through nanotechnology diagnostics. They offer a range of innovative products and services that aid in the diagnosis and management of various diseases. Their disease areas include sepsis, COVID-19, allergy, ferritin, and cSOFA.
Abionic_EN's products have been widely recognized and supported by scientific publications. They have developed a groundbreaking biomarker called Pancreatic Stone Protein (PSP), which plays a crucial role in the early detection of sepsis. This biomarker has also been proven to predict postoperative infections and trauma severity, making it essential for timely intervention and improved patient outcomes.
Additionally, Abionic_EN utilizes nanofluidics technology, enabling point-of-care protein marker analysis with rapid actionable results. Their nanotechnologies have also revolutionized in vitro IgE testing for allergies, providing a real-world comparison to a reference method. Overall, Abionic_EN's commitment to health, cutting-edge technology, and extensive scientific backing make them a leading brand in the field of nanotechnology diagnostics
Company type
Privately Held
Year founded
2010
Company size
11-50 employees
